{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:20Z","timestamp":1790050880059,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01479-y","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:27:54Z","timestamp":1760005674000},"page":"889-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efbemalenograstim Alfa, an Fc Fusion Protein, Long\u2011Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open\u2011Label Trial"],"prefix":"10.1007","volume":"45","clinical-trial-number":[{"clinical-trial-number":"nct02521441","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dongmei","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shude","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"1479_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/FTD.0000000000000701","volume":"42","author":"CE Knezevic","year":"2020","unstructured":"Knezevic CE, Clarke W. Cancer chemotherapy: the case for therapeutic drug monitoring. Ther Drug Monit. 2020;42(1):6\u201319.","journal-title":"Ther Drug Monit"},{"key":"1479_CR2","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0 [EB\/OL]. Bethesda, MD: U.S. Department of Health and Human Services; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"4","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1600-0609.2011.01658.x","volume":"87","author":"E Knudsen","year":"2011","unstructured":"Knudsen E, Iversen PO, B\u00f8yum A, Seierstad T, Nicolaysen G, Benestad HB. G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells. Eur J Haematol. 2011;87(4):302\u201311.","journal-title":"Eur J Haematol"},{"issue":"07","key":"1479_CR4","first-page":"638","volume":"26","author":"Guidelines Committee of Chinese Society of Clinical Oncology","year":"2021","unstructured":"Guidelines Committee of Chinese Society of Clinical Oncology. Chinese society of clinical oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy-related neutropenia (version 2021). Chin Clin Oncol. 2021;26(07):638\u201348.","journal-title":"Chin Clin Oncol"},{"key":"1479_CR5","unstructured":"National comprehensive cancer network. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Hematopoietic\u00a0Growth Factors, version 1.2025 [EB\/OL]. [15 October 2024]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"issue":"1","key":"1479_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332.","journal-title":"Eur J Cancer"},{"key":"1479_CR7","doi-asserted-by":"publisher","first-page":"1026377","DOI":"10.3389\/fonc.2022.1026377","volume":"12","author":"A Theyab","year":"2023","unstructured":"Theyab A, Alsharif KF, Alzahrani KJ, et al. New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy. Front Oncol. 2023;12:1026377.","journal-title":"Front Oncol"},{"issue":"23","key":"1479_CR8","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal Chem. 2016;88(23):11804\u201312.","journal-title":"Anal Chem"},{"key":"1479_CR9","doi-asserted-by":"publisher","first-page":"e2400074","DOI":"10.1200\/OA-24-00074","volume":"2","author":"JA Glaspy","year":"2025","unstructured":"Glaspy JA, Bondarenko I, Tjulandin S, et al. Efbemalenograstim alfa, a long-acting granulocyte colony-stimulating factor fusion protein without PEGylation, versus pegfilgrastim for management of chemotherapy-induced neutropenia in patients with breast cancer: results of a phase III randomized noninferiority trial. JCO Oncol Adv. 2025;2:e2400074.","journal-title":"JCO Oncol Adv"},{"key":"1479_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/17425240802650568","volume":"6","author":"P Bailon","year":"2009","unstructured":"Bailon P, Won CY, Glaspy JA, et al. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009;6:1\u201316.","journal-title":"Expert Opin Drug Deliv"},{"key":"1479_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11095-018-2505-3","volume":"35","author":"T Shimizu","year":"2018","unstructured":"Shimizu T, Abu Lila AS, Awata M, et al. A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics. Pharm Res. 2018;35:223.","journal-title":"Pharm Res"},{"issue":"21","key":"1479_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.V116.21.1485.1485","volume":"116","author":"Z Hu","year":"2010","unstructured":"Hu Z, Huang ZH, Cen XB, et al. F-627, a G-CSF dimer, stimulated a more rapid neutrophil recovery in cyclophosphamide-treated monkeys compared to monomer rhG-CSFs. Blood. 2010;116(21):1485.","journal-title":"Blood"},{"key":"1479_CR13","unstructured":"Ryzneuta, 2023. RYZNEUTA\u00ae (efbemalenograstim alfa-vuxw) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761134s000lbl.pdf."},{"issue":"3","key":"1479_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1089\/jpm.2021.0599","volume":"25","author":"AM Mischel","year":"2022","unstructured":"Mischel AM, Rosielle DA. Eastern Cooperative Oncology Group Performance Status #434. J Palliat Med. 2022;25(3):508\u201310.","journal-title":"J Palliat Med"},{"key":"1479_CR15","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03. Blood and Lymphatic System Disorders. 2010."},{"key":"1479_CR16","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) version 18.0 [EB\/OL]. Geneva: ICH; 2015. Official MedDRA website URL"},{"key":"1479_CR17","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 [EB\/OL]. Bethesda, MD: U.S. Department of Health and Human Services; 2010. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"8","key":"1479_CR18","doi-asserted-by":"publisher","first-page":"e1233","DOI":"10.1634\/theoncologist.2020-0105","volume":"25","author":"LS Schwartzberg","year":"2020","unstructured":"Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, et al. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. Oncologist. 2020;25(8):e1233\u201341.","journal-title":"Oncologist"},{"issue":"3","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol. 2002;20(3):727\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29\u201335.","journal-title":"Ann Oncol"},{"issue":"4","key":"1479_CR21","first-page":"1137","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer. 2015;23(4):1137\u201343.","journal-title":"Support Care Cancer"},{"issue":"17","key":"1479_CR22","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1002\/cam4.3227","volume":"9","author":"PW Cobb","year":"2020","unstructured":"Cobb PW, Moon YW, Mezei K, L\u00e1ng I, Bhat G, Chawla S, et al. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): a phase 3 study. Cancer Med. 2020;9(17):6234\u201343.","journal-title":"Cancer Med"},{"issue":"3","key":"1479_CR23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4143\/crt.2022.987","volume":"55","author":"YW Moon","year":"2023","unstructured":"Moon YW, Kim SK, Lee KS, Lee MH, Park YH, Park KH, et al. Eflapegrastim versus pegfilgrastim for chemotherapy-induced neutropenia in Korean and Asian patients with early breast cancer: results from the two phase III ADVANCE and RECOVER studies. Cancer Res Treat. 2023;55(3):766\u201377.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"1479_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/CBC.2003.n.003","volume":"3","author":"E Kubista","year":"2003","unstructured":"Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3(6):391\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"13","key":"1479_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"14","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer. 2013;14(13):386.","journal-title":"BMC Cancer"},{"issue":"18","key":"1479_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2019.07.95","volume":"7","author":"F Xu","year":"2019","unstructured":"Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med. 2019;7(18):482.","journal-title":"Ann Transl Med"},{"issue":"1","key":"1479_CR27","volume":"32","author":"J Glaspy","year":"2023","unstructured":"Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, et al. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023;32(1):34.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1479_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1186\/s12885-024-12892-5","volume":"24","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Wang Z, Yao W, et al. A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer. BMC Cancer. 2024;24(1):1143.","journal-title":"BMC Cancer"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01479-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:57:28Z","timestamp":1760774248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01479-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01479-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Institutional Review Boards and Ethics Committees at Fudan University Shanghai Cancer Center (review ID: 1404134-7; approval date: 28 April 2014); Nanfang Hospital of Southern Medical University (review ID: NFEC-2014084; approval date: 24 September 2014); Affiliated Cancer Hospital and Institute of Guangzhou Medical University (review ID: [2014] no. 10; approval date: 25 November 2014); Zhejiang Cancer Hospital (review ID: [2014] no. 23; approval date: 4 June 2014); Tongji Hospital of Tongji Medical College (review ID: XHEC-A-2014-012; approval date: 24 July 2014); Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (review ID: [2014] no. 64; approval date: 12 June 2014); The Affiliated Hospital of Qingdao University (review ID: QYFYEC 2014-018-01; approval date: 8 July 2014); Nantong Tumor Hospital (review ID: 2014-008-01; approval date: 2 June 2014); Affiliated Hospital of Jiangnan University (review ID: 2014-010-02; approval date: 25 July 2014); Jiangsu Province Hospital (review ID: 2015-MD-003 ; approval date: 13 January 2015); West China Hospital of Sichuan University (review ID: [2014] no. 81; approval date: 19 September 2014); Yunnan Cancer Hospital (review ID: YW201409; approval date: 31 December 2014); Henan Cancer Hospital (review ID: 2014ys18; approval date: 1 July 2014); Beijing Chaoyang Hospital of Capital Medical University (review ID: 2014-drug-73; approval date: 14 November 2014). The study was conducted in accordance with the Declaration of Helsinki and the Chinese Good Clinical Practice Guidelines. Written informed consent was obtained from all patients before any study-related procedure was performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets from the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Junning Cao was the coordinating principal investigator of the study and was involved in the development of study protocol, study conduct, and evaluation of the study results. Dongmei Ji, Changsheng Ye, Hongsheng Li, Hongjian Yang, Jilin Yi, Jinsong Lu, Haibo Wang, Xiaohong Xu, Dongyan Cai, Xiaoan Liu, Xi Yan, Jianyun Nie, Shude Cui, Hongchuan Jiang, and Xiaoyan Wang were involved in the study design, preparation, coordination, and evaluation of the trial. Shufang Wang, Wei Yao, and Denny\u00a0Hou were involved in drafting the manuscript. All authors read and approved the final version and agree to be accountable for the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}